Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07214545 · ClinicalTrials.gov registry record · NA

External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms

A NA study of Autism Spectrum Disorder (ASD) and Attention Deficit Disorder With Hyperactivity (ADHD), sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT07214545: Recruiting NA study of Autism Spectrum Disorder (ASD) and Attention Deficit Disorder With Hyperactivity (ADHD), sponsored by University of California, San Francisco.

NCT07214545 is a NA study of Autism Spectrum Disorder (ASD) and Attention Deficit Disorder With Hyperactivity (ADHD) that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 60 participants, below the 99-participant average among 16 other Autism Spectrum Disorder (ASD) trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07214545, a NA study of Autism Spectrum Disorder (ASD) and Attention Deficit Disorder With Hyperactivity (ADHD), is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Primary Outcome

Examine the efficacy of external Trigeminal Nerve Stimulation (eTNS) in reducing ADHD symptoms as measured by the Attention-Deficit/Hyperactivity Disorder Rating Scale-5 (ADHD-RS-5; range 0-54), where higher scores indicate worse symptoms.

Interventions

  • DEVICE Trigeminal Nerve Stimulation
  • DEVICE Sham Trigeminal Nerve Stimulation

Study Locations (1)

California

  • UCSF Nancy Friend Pritzker Psychiatry Building - San Francisco

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-10-06
Est. Completion 2028-01-31
Phase NA

What NCT07214545 shows while recruiting

NCT07214545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 99-participant average among 16 other Autism Spectrum Disorder (ASD) trials with a reported enrollment target (39% lower).

The record links to 2 conditions, with Autism Spectrum Disorder (ASD) appearing as the primary indexed condition, and to 2 interventions - of which Trigeminal Nerve Stimulation is the first listed.

NCT07214545 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07214545 about?

NCT07214545 is a clinical study titled "External Trigeminal Nerve Stimulation for Children With ASD + ADHD to Reduce Elevated Symptoms". The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ...

What is the current status of trial NCT07214545?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-10-06. Estimated completion is 2028-01-31.

What conditions does trial NCT07214545 study?

This clinical trial studies the following conditions: Autism Spectrum Disorder (ASD), Attention Deficit Disorder With Hyperactivity (ADHD).

What interventions are being tested in trial NCT07214545?

The interventions under investigation include: Trigeminal Nerve Stimulation (DEVICE), Sham Trigeminal Nerve Stimulation (DEVICE).

Who is sponsoring clinical trial NCT07214545?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07214545 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism Spectrum Disorder (ASD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07214545's enrollment target sits among peer trials

60 8th of 16 higher than 9 of 16 other Autism Spectrum Disorder (ASD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autism Spectrum Disorder (ASD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07214545, the US trial registry maintained by the National Library of Medicine. NCT07214545 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.